IP Library Granted Patent US 7,662,107
Granted Patent B2
US 7,662,107 · App. 11/464,264 · Granted Feb 16, 2010

Use of 1,1,1,2-Tetrafluoroethane for measuring lung function, especially for determining the functional residual capacity (FRC) of the lungs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,662,107
App. No.
11/464,264
Granted
Feb 16, 2010
Kind
B2
Abstract

1,1,1,2-Tetrafluoroethane (norflurane) is used as a tracer/trace gas for measuring the lung function because of its simple detectability, physiological harmlessness, environmental friendliness and ready availability. Especially advantageous is the possibility of the optical concentration measurement of 1,1,1,2-tetrafluoroethane for the measurement of the lung function and especially for the determination of the FRC during respiration during anesthesia, without cross sensitivity occurring during the measurement with respect to anesthetics.

Claims (24)

1. A method comprising:

providing a gas including a breathing gas with 1,1,1,2-tetrafluoroethane as a trace gas;

delivering said breathing gas with the 1,1,1,2-tetrafluoroethane trace gas to the lungs of a subject via one of an anesthesia apparatus and a respirator; and

measuring lung function of the subject during inhalation with one of said anesthesia apparatus and said respirator based on the 1,1,1,2-tetrafluoroethane trace gas, wherein said step of measuring lung function includes determining the functional residual capacity (FRC) of the lungs.

2. A method according to claim 1 , wherein FRC of the lungs is determined by washout.

3. A method according to claim 1 , wherein the 1,1,1,2-tetrafluoroethane is a component of an inhalation composition used during respiration/anesthesia.

4. A method according to claim 3 , wherein the inhalation composition includes at least one drug.

5. A method according to claim 1 , wherein said gas includes said breathing gas with 1,1,2,3,3,3,-heptafluoropropane as another trace gas, wherein the quantity ratio of the two trace gases 1,1,1,2,3,3,3-heptafluoropropane:1,1,1,2-tetrafluoroethane ranges from 1:2 to 1:3 as the maximum.

6. A method according to claim 1 , wherein concentration during respiration of the trace gas 1,1,1,2-tetrafluoroethane is about 1 vol. % to 5 vol. %, maximum of the inspired breathing gas volume present in the lungs.

7. A method according to claim 6 , wherein concentration during respiration of the trace gas 1,1,1,2-tetrafluoroethane is 0.1 vol. % to 1 vol. % of the inspired breathing gas volume present in the lungs.

8. A method according to claim 1 , wherein said gas includes said breathing gas with 1,1,2,3,3,3-heptafluoropropane as another trace gas, wherein concentration during respiration of the trace gas 1,1,1,2-tetrafluoroethane combined with 1,1,1,2,3,3,3-heptafluoropropane is about 0.1 vol. % to 1 vol. %, of the inspired breathing gas volume present in the lungs.

9. A method according to claim 1 , wherein using the 1,1,1,2-tetrafluoroethane trace gas to measure lung function includes dispensing 1,1,1,2-tetrafluoroethane continuously per breath by means of a spray dispenser during respiration.

10. A method comprising:

providing a gas including a breathing gas with 1,1,1,2-tetrafluoroethane as a trace gas and a predetermined concentration of 1,1,1,2,3,3,3-heptafluoropropane as another trace gas;

delivering said breathing gas with the 1,1,1,2-tetrafluoroethane trace gas and the 1,1,1,2,3,3,3-heptafluoropropane trace gas to the lungs of a subject via one of an anesthesia apparatus and a respirator; and

measuring lung function of the subject during inhalation with one of said anesthesia apparatus and said respirator based on the 1,1,1,2-tetrafluoroethane trace gas and the 1,1,1,2,3,3,3-heptafluoropropane trace gas, wherein a concentration during respiration of the trace gas 1,1,1,2-tetrafluoroethane combined with 1,1,1,2,3,3,3-heptafluoropropane trace gas is about 1 vol. % to 5 vol. %, maximum of the inspired breathing gas volume present in the lungs, said step of measuring lung function including determining a functional residual capacity (FRC) of the lungs of the subject.

11. A method comprising:

providing a gas comprising a breathing gas with 1,1,1,2-tetrafluoroethane as a trace gas;

delivering said breathing gas with the 1,1,1,2-tetrafluoroethane trace gas to the lungs of a subject via one of an anesthesia apparatus and a respirator; and

measuring lung function of the subject during inhalation with one of said anesthesia apparatus and said respirator based on the 1,1,1,2-tetrafluoroethane trace gas, wherein the 1,1,1,2-tetrafluoroethane trace gas is dispensed continuously per breath by means of a spray dispenser during respiration, said step of measuring lung function including determining a functional residual capacity (FRC) of the lungs of the subject.

12. A method according to claim 1 , wherein said breathing gas comprises 1,1,1,2,3,3,3,-heptafluoropropane as another trace gas, said breathing gas with said 1,1,1,2-tetrafluoroethane trace gas and said 1,1,1,2,3,3,3,-heptafluoropropane trace gas being delivered to the subject via one of said anesthesia apparatus and said respirator, said lung function being measured based on the 1,1,1,2-tetrafluoroethane trace gas and the 1,1,1,2,3,3,3-heptafluoropropane trace gas.

13. A method according to claim 12 , wherein the quantity ratio of the two trace gases 1,1,1,2,3,3,3-heptafluoropropane:1,1,1,2-tetrafluoroethane ranges from 1:2 to 1:3 as the maximum.

14. A method according to claim 11 , wherein concentration during respiration of the trace gas 1,1,1,2-tetrafluoroethane is about 1 vol. % to 5 vol. %, maximum of the inspired breathing gas volume present in the lungs.

15. A method according to claim 14 , wherein concentration during respiration of the trace gas 1,1,1,2-tetrafluoroethane is 0.1 vol. % to 1 vol. % of the inspired breathing gas volume present in the lungs.

Assignments (3)
MERGER Recorded Sep 11, 2015
From: DRAEGER MEDICAL GMBH; DRÄGERWERK AG & CO. KGAA
To: DRÄGERWERK AG & CO. KGAA
Reel/Frame 036586/0718 →
CHANGE OF NAME Recorded Oct 15, 2010
From: DRAEGER MEDICAL AG & CO. KG
To: DRAEGER MEDICAL GMBH
Reel/Frame 025137/0643 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2006
From: DICKS, BERND MICHAEL; KOCH, JOCHIM
To: DRAEGER MEDICAL AG & CO. KG
Reel/Frame 018100/0626 →